Deal overview
| Target | VIFOR PHARMA AG |
|---|---|
| Bidder | CSL LIMITED |
| Price | £100.00 Full version or £25.00 Light version |
| Publication Date | Dec 14, 2021 |
| Abstract | On 14 December 2021, the quoted Australian pharmaceutical company CSL Limited ("CSL") announced a recommended cash offer for the quoted Swiss company Vifor Pharma AG ("Vifor Pharma"). The cash offer of US$ 179.25 per share, equivalent to CHF 167 per share, valued 100% of Vifor Pharma's equity at CHF 10.9 billion. The offer, which would have a minimum acceptance threshold of ... |
| Number of pages (Full version) | 10 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
